WO1994025476A1 - Proteines de recombinaison de type augmentant la permeabilite bactericide (bpi) et de type fixant le liposaccharide (lbd), molecules codant pour ces proteines, leurs procedes de production et leurs utilisations - Google Patents

Proteines de recombinaison de type augmentant la permeabilite bactericide (bpi) et de type fixant le liposaccharide (lbd), molecules codant pour ces proteines, leurs procedes de production et leurs utilisations Download PDF

Info

Publication number
WO1994025476A1
WO1994025476A1 PCT/US1994/004709 US9404709W WO9425476A1 WO 1994025476 A1 WO1994025476 A1 WO 1994025476A1 US 9404709 W US9404709 W US 9404709W WO 9425476 A1 WO9425476 A1 WO 9425476A1
Authority
WO
WIPO (PCT)
Prior art keywords
bpi
lbp
chimera
lps
variant
Prior art date
Application number
PCT/US1994/004709
Other languages
English (en)
Inventor
Randal W. Scott
Marian N. Marra
Original Assignee
Incyte Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals, Inc. filed Critical Incyte Pharmaceuticals, Inc.
Priority to AU69429/94A priority Critical patent/AU6942994A/en
Priority to JP6524554A priority patent/JPH08511682A/ja
Priority to EP94917901A priority patent/EP0760849A1/fr
Priority to CA002161971A priority patent/CA2161971A1/fr
Publication of WO1994025476A1 publication Critical patent/WO1994025476A1/fr
Priority to US08/431,517 priority patent/US6265187B1/en
Priority to US09/861,400 priority patent/US20020146761A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des molécules d'acide nucléique recombinées codant pour un variant de BPI, un variant de LBP, une chimère LBP-BPI, une chimère BPI-IgG, et une chimère LBP-IgG, ou une chimère LBP-BPI-IgG, ainsi que les protéines pour lesquelles codent ces dernières. L'invention porte également sur des systèmes de vecteurs hôtes utilisés pour la production d'un variant de BPI, d'un variant de LBP, d'une chimère LBP-BPI, d'une chimère BPI-IgG, d'une chimère LBP-IgG, ou d'une chimère LBP-BPI-IgG, et sur leurs procédés d'utilisation pour produire lesdites protéines. L'invention se rapporte également à une composition pharmaceutique contenant un variant de BPI, un variant de LBP, une chimère LBP-BPI, une chimère BPI-IgG, une chimère LBP-IgG ou une chimère LBP-BPI-IgG en doses pharmaceutiquement efficaces, ainsi qu'un excipient pharmaceutiquement acceptable, et à son procédé d'utilisation pour traiter un sujet souffrant d'une affection liée à l'endotoxine. Un procédé permettant de prévenir toute affection liée à l'endotoxine chez un sujet consistant à administrer à ce dernier une dose prophylactique efficace d'un variant de BPI, d'un variant de LBP, d'une chimère LBP-BPI, d'une chimère BPI-IgG et d'une chimère LBP-IgG est également décrit.
PCT/US1994/004709 1989-02-14 1994-04-29 Proteines de recombinaison de type augmentant la permeabilite bactericide (bpi) et de type fixant le liposaccharide (lbd), molecules codant pour ces proteines, leurs procedes de production et leurs utilisations WO1994025476A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU69429/94A AU6942994A (en) 1993-04-30 1994-04-29 Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
JP6524554A JPH08511682A (ja) 1993-04-30 1994-04-29 組み換えｂｐｉ蛋白およびｌｂｐ蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用
EP94917901A EP0760849A1 (fr) 1993-04-30 1994-04-29 Proteines de recombinaison de type augmentant la permeabilite bactericide (bpi) et de type fixant le liposaccharide (lbd), molecules codant pour ces proteines, leurs procedes de production et leurs utilisations
CA002161971A CA2161971A1 (fr) 1993-04-30 1994-04-29 Proteines recombinantes a base de bpi et de lbp; molecules d'acide nucleique codant ces proteines; methodes de preparation et utilisations
US08/431,517 US6265187B1 (en) 1989-02-14 1995-05-01 Recombinant endotoxin-neutralizing proteins
US09/861,400 US20020146761A1 (en) 1989-02-14 2001-05-18 Recombinant endotoxin-neutralizing proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5629293A 1993-04-30 1993-04-30
US08/056,292 1993-04-30
US16571793A 1993-12-10 1993-12-10
US08/165,717 1993-12-10

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1991/005758 Continuation-In-Part WO1992003535A1 (fr) 1989-02-14 1991-08-13 Proteines bpi recombinees, utilisation et procedes de preparation de ces proteines
US07/915,720 Continuation-In-Part US5770694A (en) 1989-02-14 1992-07-22 Genetically engineered BPI variant proteins
US16571793A Continuation-In-Part 1989-02-14 1993-12-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/431,517 Continuation-In-Part US6265187B1 (en) 1989-02-14 1995-05-01 Recombinant endotoxin-neutralizing proteins
US09/861,400 Continuation-In-Part US20020146761A1 (en) 1989-02-14 2001-05-18 Recombinant endotoxin-neutralizing proteins

Publications (1)

Publication Number Publication Date
WO1994025476A1 true WO1994025476A1 (fr) 1994-11-10

Family

ID=26735192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/004709 WO1994025476A1 (fr) 1989-02-14 1994-04-29 Proteines de recombinaison de type augmentant la permeabilite bactericide (bpi) et de type fixant le liposaccharide (lbd), molecules codant pour ces proteines, leurs procedes de production et leurs utilisations

Country Status (5)

Country Link
EP (1) EP0760849A1 (fr)
JP (1) JPH08511682A (fr)
AU (1) AU6942994A (fr)
CA (1) CA2161971A1 (fr)
WO (1) WO1994025476A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034873A1 (fr) * 1995-05-01 1996-11-07 Incyte Pharmaceuticals, Inc. Proteines de recombinaison neutralisant une endotoxine
WO1997042966A1 (fr) * 1996-05-10 1997-11-20 Xoma Corporation Applications therapeutiques de produits proteiques bactericides/augmentant la permeabilite (bpi) dans le cas de meningococcemies chez l'homme
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
US5756464A (en) * 1996-05-23 1998-05-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma
US5780429A (en) * 1995-12-22 1998-07-14 Marine Biological Laboratory Anti-LPS factor from horseshoe crabs and methods of use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5804367A (en) * 1994-01-24 1998-09-08 Xoma Corporation Method for quantifying LBP in body fluids
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5856438A (en) * 1993-03-12 1999-01-05 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
EP0890648A1 (fr) * 1996-12-10 1999-01-13 Council of Scientific & Industrial Research Lipopolysaccharide non toxique et sa préparation
DE19729810A1 (de) * 1997-07-11 1999-01-14 Max Delbrueck Centrum Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US5891618A (en) * 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6486125B1 (en) 1996-05-24 2002-11-26 Regents Of The University Of Minnesota Synthesis of soluble β-sheet forming peptides
EP1310558A2 (fr) * 1993-02-02 2003-05-14 XOMA Technology Ltd. Produits protéiniques stables bactéricides ou renforcant la perméabilité et compositions pharmaceutiques les contenant
US7056514B2 (en) 2002-02-20 2006-06-06 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
ATE169030T1 (de) * 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Volume 179, No. 1, issued 30 August 1991, LARRICK et al., "Complementary DNA Sequence of Rabbit CAP18--A Unique Lipopolysaccharide Binding Protein", pages 170-175. *
JOURNAL OF EXPERIMENTAL MEDICINE, Volume 174, issued September 1991, OOI et al., "Endotoxin-Neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-Increasing Protein of Human Neutrophils", pages 649-655. *
See also references of EP0760849A4 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 264, No. 16, 05 June 1989, GRAY et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein", pages 9505-9509. *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310558A2 (fr) * 1993-02-02 2003-05-14 XOMA Technology Ltd. Produits protéiniques stables bactéricides ou renforcant la perméabilité et compositions pharmaceutiques les contenant
US6828418B2 (en) 1993-02-02 2004-12-07 Xoma Corporation Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
EP1310558A3 (fr) * 1993-02-02 2003-08-13 XOMA Technology Ltd. Produits protéiniques stables bactéricides ou renforcant la perméabilité et compositions pharmaceutiques les contenant
US5856438A (en) * 1993-03-12 1999-01-05 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5804367A (en) * 1994-01-24 1998-09-08 Xoma Corporation Method for quantifying LBP in body fluids
US5891618A (en) * 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
US6274328B1 (en) 1994-01-24 2001-08-14 Xoma Corporation Method for quantifying LBP in body fluids
US7081334B2 (en) 1994-01-24 2006-07-25 Xoma Corporation Method for quantifying LBP in body fluids
US5990086A (en) * 1994-01-24 1999-11-23 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
WO1996034873A1 (fr) * 1995-05-01 1996-11-07 Incyte Pharmaceuticals, Inc. Proteines de recombinaison neutralisant une endotoxine
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
US5780429A (en) * 1995-12-22 1998-07-14 Marine Biological Laboratory Anti-LPS factor from horseshoe crabs and methods of use
US5935930A (en) * 1996-05-10 1999-08-10 Xoma Corporation Antithrombotic materials and methods
US6242418B1 (en) 1996-05-10 2001-06-05 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
WO1997042966A1 (fr) * 1996-05-10 1997-11-20 Xoma Corporation Applications therapeutiques de produits proteiques bactericides/augmentant la permeabilite (bpi) dans le cas de meningococcemies chez l'homme
US5888977A (en) * 1996-05-10 1999-03-30 Giroir; Brett P. Therapeutic uses of BPI protein products for human meningococcemia
US6599881B1 (en) 1996-05-10 2003-07-29 Xoma Corporation Antithrombotic materials and methods
US6596691B2 (en) 1996-05-10 2003-07-22 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
US6107280A (en) * 1996-05-10 2000-08-22 Xoma Corporation Antithrombotic materials and methods
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
US5945399A (en) * 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US5756464A (en) * 1996-05-23 1998-05-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma
US7030087B2 (en) 1996-05-24 2006-04-18 Regents Of The University Of Minnesota Synthetic approach to designed chemical structures
US6486125B1 (en) 1996-05-24 2002-11-26 Regents Of The University Of Minnesota Synthesis of soluble β-sheet forming peptides
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6162788A (en) * 1996-08-09 2000-12-19 Xoma Corporation Uses of BPI protein products
US6583116B1 (en) 1996-08-09 2003-06-24 Xoma Corporation Anti-chlamydial methods and materials
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
EP0890648A1 (fr) * 1996-12-10 1999-01-13 Council of Scientific & Industrial Research Lipopolysaccharide non toxique et sa préparation
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
DE19729810A1 (de) * 1997-07-11 1999-01-14 Max Delbrueck Centrum Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung
DE19729810C2 (de) * 1997-07-11 2000-01-13 Max Delbrueck Centrum Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung
US6949512B1 (en) * 1997-07-11 2005-09-27 Max-Delbruck-Zentrum Fur Molekulare Medizin Therapeutic agent for the treatment of septicaemia its preparation and use
WO1999002178A1 (fr) * 1997-07-11 1999-01-21 Max-Delbrück-Centrum für Molekulare Medizin Agent therapeutique pour le traitement de la septicemie, sa preparation et son utilisation
US6306824B1 (en) 1997-10-22 2001-10-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US6087126A (en) * 1998-06-19 2000-07-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6599880B1 (en) 1998-06-19 2003-07-29 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US7056514B2 (en) 2002-02-20 2006-06-06 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US7339023B2 (en) 2002-02-20 2008-03-04 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides

Also Published As

Publication number Publication date
CA2161971A1 (fr) 1994-11-10
JPH08511682A (ja) 1996-12-10
EP0760849A1 (fr) 1997-03-12
EP0760849A4 (fr) 1996-12-02
AU6942994A (en) 1994-11-21

Similar Documents

Publication Publication Date Title
WO1994025476A1 (fr) Proteines de recombinaison de type augmentant la permeabilite bactericide (bpi) et de type fixant le liposaccharide (lbd), molecules codant pour ces proteines, leurs procedes de production et leurs utilisations
US5171739A (en) Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
Borregaard et al. Stimulus-dependent secretion of plasma proteins from human neutrophils.
US5334584A (en) Recombinant, non-glycosylated bpi protein and uses thereof
EP0610445B1 (fr) Utilisation de compositions comprenant une proteine a action bactericide/accroissant la permeabilite et un excipient lipidique
US5308834A (en) Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5731415A (en) Lipopolysaccharide binding protein derivatives
Tan et al. High‐affinity LPS binding domain (s) in recombinant factor C of a horseshoe crab neutralizes LPS‐induced lethality
US20060093614A1 (en) Platelet glycoprotein Ib alpha fusion polypeptides and methods of use thereof
US6265187B1 (en) Recombinant endotoxin-neutralizing proteins
JPH09500269A (ja) 殺菌性／透過性が増大したグリコシル化及び非グリコシル化タンパク質及びその製造方法
JP2002518011A (ja) 殺菌性／透過性増加タンパク質（ｂｐｉ）欠失アナログ
EP0550506B1 (fr) Nouveau facteur chimiotactique
US5770694A (en) Genetically engineered BPI variant proteins
AU2003233008A1 (en) Fusion polypeptides and methods for inhibiting microbial adhesion
US5990082A (en) Uses of lipopolysaccharide binding protein
US6093801A (en) Recombinant analogs of bactericidal/permeability increasing protein
JPH08507212A (ja) 突然変異型タンパク質並びにそれを製造及び用いるための方法及び物質
AU652575B2 (en) Novel chemotactic factor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2161971

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994917901

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994917901

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994917901

Country of ref document: EP